An emergency physician describes the risks he sees from IV wellness infusions
Sollis Health’s Scott Braunstein described infusion complications he has seen in emergency care. Harley Pasternak discussed the origins of the 10,000-step goal.
LAS VEGAS — The people administering wellness infusions can pose a risk alongside the ingredients in the bag, Sollis Health Chief Medical Officer Dr. Scott Braunstein said Monday at HLTH. He said his emergency-care work has brought him patients with complications including bleeding, bruising and inflammation around an IV site.
Braunstein led the onstage questions in Optimize Out of the ER, a Revv Stage discussion with fitness and nutrition author Harley Pasternak. Pasternak identified himself as a Sollis member and described his experience with the concierge urgent-care provider before the two turned to wellness trends.
What shows up in emergency care
Braunstein said he has seen “palpitations, arrhythmias, vomiting, chest pain” in connection with wellness infusions. He said “unqualified people are placing the IV” in some cases, creating risks apart from whatever the infusion contains.
The pair also questioned commercial detox services. Mayo Clinic guidance says colon cleansing has no established detox benefit and can cause complications, including dehydration and injury to the rectum. Braunstein put both examples in the context of products and services reaching patients through social media.
Pasternak said he had seen wellness infusions offered in settings such as a gym, and recalled a client who had an allergic reaction after receiving one. His account was anecdotal, as were Braunstein’s descriptions of what came through emergency care. Together the examples explained why the speakers were interested in both the contents of an infusion and the conditions under which it was given.
The risks they discussed arise at different points. An infusion may contain a substance whose effects have not been established for the promised use. The preparation itself can present quality problems, and the person inserting or monitoring the IV has to recognize when something is going wrong. An advertised list of ingredients tells a patient little about those last two steps.
Federal regulators have documented problems with some preparations used for intravenous administration. In one FDA warning, the agency said patients had reported fever, chills and other reactions after receiving compounded injectable glutathione made from a dietary supplement-grade ingredient. The agency said that grade was inappropriate for injectable drugs and cited the risk of endotoxin exposure. The notice concerns a particular compounding issue and illustrates why preparation standards matter separately from the ingredient on the label.
One label can cover very different products
Braunstein also asked about peptides sold directly to consumers. Pasternak distinguished widely used medicines such as insulin from products whose safety and efficacy have not been established for the uses advertised online. The important distinction is the evidence for a given drug, formulation and indication.
The FDA’s review of some compounds identifies concerns including impurities, how ingredients are characterized and possible immune reactions. For some substances, the agency says available human safety information is limited. Those are specific findings about specific ingredients, rather than a finding that the same risk applies to every medicine that falls into the broad category.
The conversation moved from things patients can buy online to procedures with a medical appearance. Braunstein’s examples emphasized that a person deciding whether to pursue a service may see the product’s promotion before ever encountering a clinician who can put that service within the context of their health history.
Revisiting a familiar fitness target
Pasternak described the 10,000-step target he helped popularize as “merely observational,” explaining that he had noticed differences in how much people walked while researching a book. He said walking “doesn’t have to be all at once” and described movement and strength training as habits he discusses with clients.
Pasternak said he came to the step count after comparing patterns of activity while researching a book. What he wanted people to take from it was the opportunity to walk during an ordinary day, including for transportation or with other people. He also discussed resistance exercise and the importance of finding a routine patients can repeat. He spoke from his work as a fitness and nutrition professional.
The closing section returned to the contrast between a product available for purchase and a sustained change in how someone moves or trains. Pasternak described the questions he gets from clients considering a new trend. Braunstein described the complications that can bring a patient to immediate care, a vantage point that made the discussion concrete even where the speakers gave no population-level estimate of how frequently those complications occur.
The conversation left an opening for clinicians to ask which wellness products, services and goals patients are already trying. Pasternak hears those questions from clients before they act, while Braunstein said he often sees the consequences after something goes wrong.
Pasternak also told the audience why he appeared on a panel about emergency medicine. He said he had joined Sollis after seeing how long it took his wife to get care for a cut. He later described a shorter experience when she received treatment at the membership service. The comparison came from a member’s own account and gives context for his relationship to the company whose chief medical officer was asking the questions.
Braunstein’s examples concerned patients who arrived after something had gone wrong. Emergency clinicians may need to establish what was given and where it came from, along with what happened during and after administration. The details in a sales listing or an appointment receipt may not answer those questions. His description of problems around the IV site made a broader point about the difference between an adverse reaction and a complication of administration.
The two also discussed a habit Pasternak sees in his work: clients ask about a trend after being exposed to it repeatedly or after already deciding to try it. That can make the clinical conversation more specific than a general warning about online information. A patient may be asking about the ingredient, the intended benefit or the setting where the service is offered. The questions lead to different kinds of evidence.
That was also the value of revisiting a target as familiar as 10,000 steps. Pasternak explained how he arrived at it, giving the audience a way to separate the motivation to move more from any claim that a particular number has a universal meaning. He described activity that fits into an ordinary day and training that can be repeated over time.